Psyence Biomedical Ltd. Common Shares

Psyence Biomedical Ltd. is an integrated biopharmaceutical company focused on developing botanical psilocybin-based psychedelic medicines. Its lead product candidate, NPX-5, is a botanical drug in a Phase IIb clinical study for the treatment of adjustment disorder in cancer patients in a palliative care setting. The company is based in Toronto, Canada, and is a subsidiary of Psyence Group Inc.